These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 36998249)

  • 1. Efficacy and Safety of Advanced Therapies for Moderately to Severely Active Ulcerative Colitis at Induction and Maintenance: An Indirect Treatment Comparison Using Bayesian Network Meta-analysis.
    Panaccione R; Collins EB; Melmed GY; Vermeire S; Danese S; Higgins PDR; Kwon CS; Zhou W; Ilo D; Sharma D; Sanchez Gonzalez Y; Wang ST
    Crohns Colitis 360; 2023 Apr; 5(2):otad009. PubMed ID: 36998249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
    Danese S; Vermeire S; Zhou W; Pangan AL; Siffledeen J; Greenbloom S; Hébuterne X; D'Haens G; Nakase H; Panés J; Higgins PDR; Juillerat P; Lindsay JO; Loftus EV; Sandborn WJ; Reinisch W; Chen MH; Sanchez Gonzalez Y; Huang B; Xie W; Liu J; Weinreich MA; Panaccione R
    Lancet; 2022 Jun; 399(10341):2113-2128. PubMed ID: 35644166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matching-Adjusted Indirect Comparisons of Filgotinib vs Vedolizumab, Tofacitinib, and Ustekinumab for Moderately to Severely Active Ulcerative Colitis.
    Lu X; Zhou ZY; Xin Y; Wang MJ; Gray E; Jairath V; Lindsay JO
    Inflamm Bowel Dis; 2024 Jan; 30(1):64-77. PubMed ID: 36946138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Efficacy and Safety of Upadacitinib vs. Vedolizumab, Ustekinumab, and Tofacitinib After Induction and Maintenance for Ulcerative Colitis: Three Matching-Adjusted Indirect Comparisons.
    Reinisch W; Melmed GY; Nakase H; Seidelin J; Ma C; Xuan S; Tran J; Remple V; Wegrzyn L; Levy G; Sanchez Gonzalez Y; Panaccione R
    Adv Ther; 2024 Oct; 41(10):3832-3849. PubMed ID: 39126596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.
    Lasa JS; Olivera PA; Danese S; Peyrin-Biroulet L
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):161-170. PubMed ID: 34856198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis.
    Singh S; Murad MH; Fumery M; Dulai PS; Sandborn WJ
    Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2179-2191.e6. PubMed ID: 31945470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis.
    Lu X; Jarrett J; Sadler S; Tan M; Dennis J; Jairath V
    Int J Clin Pharm; 2023 Apr; 45(2):330-341. PubMed ID: 36484968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis.
    Hibi T; Kamae I; Pinton P; Ursos L; Iwakiri R; Hather G; Patel H
    Intest Res; 2021 Jan; 19(1):53-61. PubMed ID: 32312035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of mirikizumab compared with currently approved biologic drugs for the treatment of ulcerative colitis: A systematic review and network meta-analysis.
    Moćko P; Koperny M; Śladowska K; Holko P; Kowalska-Bobko I; Kawalec P
    Pharmacotherapy; 2024 Oct; 44(10):811-821. PubMed ID: 39320112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
    Feagan BG; Danese S; Loftus EV; Vermeire S; Schreiber S; Ritter T; Fogel R; Mehta R; Nijhawan S; Kempiński R; Filip R; Hospodarskyy I; Seidler U; Seibold F; Beales ILP; Kim HJ; McNally J; Yun C; Zhao S; Liu X; Hsueh CH; Tasset C; Besuyen R; Watanabe M; Sandborn WJ; Rogler G; Hibi T; Peyrin-Biroulet L
    Lancet; 2021 Jun; 397(10292):2372-2384. PubMed ID: 34090625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The comparative efficacy and safety of biologics and small molecules for treating patients with ulcerative colitis in Portugal: a systematic literature review and network meta-analysis.
    Sanchez Gonzalez Y; Prata R; Alves D
    Eur Rev Med Pharmacol Sci; 2023 Jul; 27(14):6744-6759. PubMed ID: 37522686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the economics of biologic and small molecule therapies for the treatment of moderate to severe ulcerative colitis in Japan: a cost per responder analysis of upadacitinib.
    Saruta M; Kawaguchi I; Ogawa Y; Sanchez Gonzalez Y; Numajiri N; Tang X; Miller R
    J Med Econ; 2024; 27(1):566-574. PubMed ID: 38512101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Advanced Therapies in Moderately-to-Severely Active Ulcerative Colitis: a Systematic Review and Network Meta-analysis.
    Dignass A; Ainsworth C; Hartz S; Dunnewind N; Redondo I; Sapin C; Kroep S; Halfpenny N; Arcà E; Hoque S
    Adv Ther; 2024 Dec; 41(12):4446-4462. PubMed ID: 39404996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitis.
    Jairath V; Cohen RD; Loftus EV; Candela N; Lasch K; Schultz BG
    BMC Gastroenterol; 2022 Dec; 22(1):501. PubMed ID: 36474165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Speed of Early Symptomatic Remission With Advanced Therapies for Moderate-to-Severe Ulcerative Colitis: A Systematic Review and Network Meta-Analysis.
    Ahuja D; Murad MH; Ma C; Jairath V; Singh S
    Am J Gastroenterol; 2023 Sep; 118(9):1618-1625. PubMed ID: 36976548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis.
    Vickers AD; Ainsworth C; Mody R; Bergman A; Ling CS; Medjedovic J; Smyth M
    PLoS One; 2016; 11(10):e0165435. PubMed ID: 27776175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis.
    Jairath V; Chan K; Lasch K; Keeping S; Agboton C; Blake A; Patel H
    Expert Rev Gastroenterol Hepatol; 2021 Jun; 15(6):711-722. PubMed ID: 33599181
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of ustekinumab vs. advanced therapies for the treatment of moderately to severely active ulcerative colitis: a systematic review and network meta-analysis.
    Welty M; Mesana L; Padhiar A; Naessens D; Diels J; van Sanden S; Pacou M
    Curr Med Res Opin; 2020 Apr; 36(4):595-606. PubMed ID: 31960724
    [No Abstract]   [Full Text] [Related]  

  • 19. Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation.
    Lohan C; Diamantopoulos A; LeReun C; Wright E; Bohm N; Sawyer LM
    BMJ Open Gastroenterol; 2019; 6(1):e000302. PubMed ID: 31413856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative onset of effect of biologics and small molecules in moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.
    Attauabi M; Dahl EK; Burisch J; Gubatan J; Nielsen OH; Seidelin JB
    EClinicalMedicine; 2023 Mar; 57():101866. PubMed ID: 36864986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.